查看購物車
  • Simplified Chinese
  • English
  • Japanese
2021-2031 年北美基因檢測服務市場報告（範圍、細分、動態和競爭分析）
市場調查報告書
商品編碼
1819710

2021-2031 年北美基因檢測服務市場報告（範圍、細分、動態和競爭分析）

North America Genetic Testing Services Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 176 Pages | 訂單完成後即時交付

價格

北美基因檢測服務市場預計將實現顯著成長，預計到 2031 年將達到約 58.9293 億美元，高於 2023 年的 18.0802 億美元。這一成長軌跡表明，2023 年至 2031 年的年複合成長率(CAGR) 為 15.9%。

執行摘要和市場分析

北美基因檢測服務產業正在經歷大幅擴張，這主要得益於技術進步、個人化醫療需求的不斷成長以及對預防性醫療保健的日益重視。美國是該市場的主要參與者，其特點是基因檢測廣泛應用於各種領域，包括癌症診斷、產前篩檢和遺傳性疾病的鑑定。 23andMe、Illumina 和 LabCorp 等知名公司的加入，透過不斷創新和改進檢測技術，進一步推動了市場的成長。此外，政府支持基因組學研究的措施和醫療保健資金的增加預計將顯著促進市場成長，鞏固北美作為全球基因檢測服務領導者的地位。

市場區隔分析

基因檢測服務市場可以根據服務類型、疾病和服務提供者進行細分。

  • 服務類型：市場分為幾類，包括預測性檢測、帶因者檢測、產前檢測、新生兒篩檢、診斷性基因檢測等。 2023年，預測性檢測領域成為市場的最大貢獻者。
  • 疾病：市場也依疾病細分，包括癌症、心血管疾病、代謝失調和其他疾病。癌症領域在2023年佔據了最大的市場佔有率，反映了基因檢測在癌症風險評估和管理中的重要作用。
  • 服務提供者：市場分為醫院實驗室、診斷實驗室和其他服務提供者。 2023年，醫院實驗室佔據了最大的佔有率，凸顯了其在提供基因檢測服務方面的關鍵作用。

市場展望

全球遺傳疾病的日益普及是推動基因檢測服務需求成長的主要因素。遺傳性疾病通常表現為罕見且非典型的症狀，其中許多目前無法治癒。根據世界衛生組織 (WHO) 2021 年的數據，每 1,000 人中約有 10 人患有單基因疾病，全球約有 7,000 萬至 8,000 萬人患有單基因疾病。全球基因組織報告稱，已發現約 7,000 種罕見疾病和病症，且新疾病仍在持續發現中。

謝菲爾德大學的研究表明，全球約有3億人患有遺傳疾病。例如，MJH Life Sciences 2022年的報告估計，每年約有30萬名新生兒被診斷​​出患有鐮狀細胞疾病，約佔全球人口的5%。此外，2023年8月發表的一項研究強調，每500名非裔美國人中就有1人患有鐮狀細胞疾病，約12分之一的非裔美國人攜帶這種常染色體隱性突變。

遺傳疾病發生率的上升是基因檢測服務市場成長的主要驅動力。

國家洞察

北美基因檢測服務市場包括美國、加拿大和墨西哥，其中美國在 2023 年佔據最大市場佔有率。根據美國疾病管制與預防中心 (CDC) 的數據，2020 年美國診斷出約 1,603,844 例新癌症病例，導致 602,347 例癌症死亡。預計 2023 年美國將新增約 1,958,310 例癌症病例，死亡人數為 609,820 人。國際癌症研究機構預計，到 2040 年，美國新發癌症發生率可能達到 3,020 萬人。許多癌症都具有遺傳成分，因此基因檢測對於評估有癌症家族史的個體的風險因素至關重要。

美國政府責任署2021年10月報告稱，美國有2500萬至3000萬人患有罕見疾病，其中近一半患者是兒童。據估計，80%的罕見疾病源自於遺傳。

在過去的幾十年裡，基因檢測已成為美國醫療保健體係不可或缺的一部分。隨著基因檢測的普及，確保全國檢測品質的需求也日益成長。 《臨床實驗室改進修正案》（CLIA）對基因檢測實驗室進行監管，確保其符合品質控制和保證標準。此外，美國食品藥物管理局（FDA）也負責監督臨床實驗室使用的基因檢測試劑盒的品質。

受癌症、自體免疫疾病和傳染病等領域應用的推動，美國對基因檢測的需求預計將持續成長。基因檢測產品的創新，例如阿韋利諾實驗室的AvaGen眼科基因檢測以及美國食品藥物管理局(FDA)批准的脆性X症候群基因檢測，都顯示了該領域的持續進步。

公司簡介

北美基因檢測服務市場的主要參與者包括 Eurofins Scientific SE、Exact Sciences Corp、Laboratory Corp of America Holdings、23andMe Holding Co、Ambry Genetics Corp、Quest Diagnostics Inc、Illumina Inc、F. Hoffmann-La Roche Ltd、NeoGenomics Inc、Cento NV Inc、VERITAS INTERCONTINENTAL 和 GeneDx, LLC。這些公司正在採用各種策略，包括擴張、產品創新和併購，以增強其市場影響力並為消費者提供創新解決方案。

目錄

第1章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：北美基因檢測服務市場格局

  • PEST分析

第5章：北美基因檢測服務市場－關鍵市場動態

  • 市場促進因素
    • 遺傳疾病盛行率上升
    • 提高對個人化醫療的認知和接受度
    • 直接面對消費者（DTC）基因檢測的偏好日益成長
  • 市場限制
    • 基因檢測的社會和倫理影響
    • 基因服務的可負擔性
  • 市場機會
    • 發展中國家尚未開發的新興市場
  • 未來趨勢
    • 人工智慧基因檢測
  • 影響分析：

第6章：基因檢測服務市場－北美分析

  • 2021-2031年北美基因檢測服務市場收入
  • 北美基因檢測服務市場預測分析

第7章：北美基因檢測服務市場分析－依服務類型

  • 預測測試
  • 攜帶者檢測
  • 產前檢查
  • 新生兒篩檢
  • 診斷性基因檢測
  • 其他

第8章：北美基因檢測服務市場分析－按疾病

  • 癌症
  • 心血管疾病
  • 代謝性疾病
  • 其他疾病

第9章：北美基因檢測服務市場分析－服務供應商

  • 醫院實驗室
  • 診斷實驗室
  • 其他服務提供者

第 10 章：北美基因檢測服務市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 11 章：基因檢測服務市場-產業格局

  • 概述
  • 基因檢測服務市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第12章：公司簡介

  • Eurofins Scientific SE
  • Exact Sciences Corp
  • Laboratory Corp of America Holdings
  • 23andMe Holding Co
  • Ambry Genetics Corp
  • Quest Diagnostics Inc
  • Illumina Inc
  • F. Hoffmann-La Roche Ltd
  • NeoGenomics Inc
  • Centogene NV
  • Ancestry Genomics Inc
  • Gene By Gene Ltd
  • SIVOTEC BioInformatics LLC
  • Progenesis
  • Fulgent Genetics, Inc
  • VERITAS INTERCONTINENTAL
  • GeneDx, LLC

第 13 章：附錄

Product Code: TIPRE00009262

The North American genetic testing services market is poised for remarkable growth, projected to reach approximately USD 5,892.93 million by 2031, up from USD 1,808.02 million in 2023. This growth trajectory indicates a compound annual growth rate (CAGR) of 15.9% from 2023 to 2031.

Executive Summary and Market Analysis

The genetic testing services sector in North America is witnessing substantial expansion, primarily fueled by advancements in technology, a rising demand for personalized medicine, and an increasing emphasis on preventive healthcare. The United States stands out as a major player in this market, characterized by the widespread use of genetic testing for various applications, including cancer diagnosis, prenatal screening, and the identification of hereditary diseases. The presence of prominent companies such as 23andMe, Illumina, and LabCorp is further propelling market growth through continuous innovation and enhancements in testing technologies. Additionally, government initiatives supporting genomics research and increased healthcare funding are expected to significantly contribute to the market's growth, solidifying North America's position as a global leader in genetic testing services.

Market Segmentation Analysis

The genetic testing services market can be segmented based on service type, disease, and service provider.

  • Service Type: The market is divided into several categories, including predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic genetic testing, and others. In 2023, the predictive testing segment emerged as the largest contributor to the market.
  • Disease: The market is also segmented by disease, including cancer, cardiovascular diseases, metabolic disorders, and other conditions. The cancer segment held the largest market share in 2023, reflecting the significant role of genetic testing in cancer risk assessment and management.
  • Service Provider: The market is categorized into hospital-based laboratories, diagnostic laboratories, and other service providers. Hospital-based laboratories accounted for the largest share in 2023, highlighting their critical role in delivering genetic testing services.

Market Outlook

The increasing prevalence of genetic diseases globally is a major factor driving the demand for genetic testing services. Genetic disorders often present with rare and atypical symptoms, many of which are currently incurable. According to the World Health Organization (WHO) in 2021, approximately 10 out of every 1,000 individuals are affected by single-gene diseases, translating to an estimated 70 to 80 million people worldwide. The Global Genes organization reports that around 7,000 rare diseases and disorders have been identified, with new conditions being discovered regularly.

Research from the University of Sheffield indicates that approximately 300 million people globally are living with genetic diseases. For instance, a 2022 report by MJH Life Sciences estimated that around 300,000 newborns are diagnosed with sickle cell disease each year, representing about 5% of the global population. Furthermore, a study published in August 2023 highlighted that 1 in 500 African Americans is affected by sickle cell disease, with about 1 in 12 carrying the autosomal recessive mutation.

This rising incidence of genetic diseases is a key driver for the growth of the genetic testing services market.

Country Insights

The North American genetic testing services market includes the United States, Canada, and Mexico, with the US holding the largest market share in 2023. According to the Centers for Disease Control and Prevention (CDC), approximately 1,603,844 new cancer cases were diagnosed in the US in 2020, resulting in 602,347 cancer-related deaths. Projections for 2023 estimate around 1,958,310 new cancer cases and 609,820 deaths. The International Agency for Research on Cancer anticipates that new cancer incidences could reach 30.2 million by 2040. Many cancers have a hereditary component, making genetic testing essential for assessing risk factors in individuals with a family history of cancer.

The US Government Accountability Office reported in October 2021 that between 25 to 30 million Americans suffer from rare diseases, with nearly half of these patients being children. It is estimated that 80% of rare diseases are genetic in origin.

Genetic testing has become integral to the US healthcare system over the past few decades. As the adoption of genetic testing increases, there is a growing need to ensure the quality of tests conducted across the country. The Clinical Laboratory Improvement Amendments (CLIA) regulate genetic testing laboratories, ensuring compliance with quality control and assurance standards. Additionally, the US Food and Drug Administration (FDA) oversees the quality of genetic testing kits used by clinical laboratories.

The demand for genetic testing in the US is expected to continue growing, driven by its applications in cancer, autoimmune diseases, and infectious diseases. Innovations in genetic testing products, such as Avellino Labs' AvaGen genetic eye test and the FDA's approval of a genetic test for Fragile X Syndrome, illustrate the ongoing advancements in this field.

Company Profiles

Key players in the North American genetic testing services market include Eurofins Scientific SE, Exact Sciences Corp, Laboratory Corp of America Holdings, 23andMe Holding Co, Ambry Genetics Corp, Quest Diagnostics Inc, Illumina Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Inc, Centogene NV, Ancestry Genomics Inc, Gene By Gene Ltd, SIVOTEC BioInformatics LLC, Progenesis, Fulgent Genetics, Inc, VERITAS INTERCONTINENTAL, and GeneDx, LLC. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. North America Genetic Testing Services Market Landscape

  • 4.1 PEST Analysis

5. North America Genetic Testing Services Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Genetic Diseases
    • 5.1.2 Increasing Awareness and Acceptance of Personalized Medicines
    • 5.1.3 Growing Preference for Direct-To-Consumer (DTC) Genetic Testing
  • 5.2 Market Restraints
    • 5.2.1 Social and Ethical Implications of Genetic Testing
    • 5.2.2 Affordability of Genetic Services
  • 5.3 Market Opportunities
    • 5.3.1 Untapped Emerging Markets in Developing Countries
  • 5.4 Future Trends
    • 5.4.1 Artificial Intelligence-Powered Genetic Testing
  • 5.5 Impact Analysis:

6. Genetic Testing Services Market - North America Analysis

  • 6.1 North America Genetic Testing Services Market Revenue (US$ Million), 2021-2031
  • 6.2 North America Genetic Testing Services Market Forecast Analysis

7. North America Genetic Testing Services Market Analysis - by Service Type

  • 7.1 Predictive Testing
    • 7.1.1 Overview
    • 7.1.2 Predictive Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Carrier Testing
    • 7.2.1 Overview
    • 7.2.2 Carrier Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Prenatal Testing
    • 7.3.1 Overview
    • 7.3.2 Prenatal Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 New-born Screening
    • 7.4.1 Overview
    • 7.4.2 New-born Screening: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Diagnostic Genetic Testing
    • 7.5.1 Overview
    • 7.5.2 Diagnostic Genetic Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Genetic Testing Services Market Analysis - by Disease

  • 8.1 Cancer
    • 8.1.1 Overview
    • 8.1.2 Cancer: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Cardiovascular Diseases
    • 8.2.1 Overview
    • 8.2.2 Cardiovascular Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Metabolic Diseases
    • 8.3.1 Overview
    • 8.3.2 Metabolic Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Other Diseases
    • 8.4.1 Overview
    • 8.4.2 Other Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Genetic Testing Services Market Analysis - by Service Providers

  • 9.1 Hospital-Based Laboratories
    • 9.1.1 Overview
    • 9.1.2 Hospital-Based Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Overview
    • 9.2.2 Diagnostic Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Other Service Providers
    • 9.3.1 Overview
    • 9.3.2 Other Service Providers: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Genetic Testing Services Market - Country Analysis

  • 10.1 North America
    • 10.1.1 North America Genetic Testing Services Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 North America Genetic Testing Services Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 United States: North America Genetic Testing Services Market Share - by Service Type
        • 10.1.1.2.2 United States: North America Genetic Testing Services Market Share - by Disease
        • 10.1.1.2.3 United States: North America Genetic Testing Services Market Share - by Cancer Disease
        • 10.1.1.2.4 United States: North America Genetic Testing Services Market Share - by Service Providers
      • 10.1.1.3 Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 Canada: North America Genetic Testing Services Market Share - by Service Type
        • 10.1.1.3.2 Canada: North America Genetic Testing Services Market Share - by Disease
        • 10.1.1.3.3 Canada: North America Genetic Testing Services Market Share - by Cancer Disease
        • 10.1.1.3.4 Canada: North America Genetic Testing Services Market Share - by Service Providers
      • 10.1.1.4 Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Mexico: North America Genetic Testing Services Market Share - by Service Type
        • 10.1.1.4.2 Mexico: North America Genetic Testing Services Market Share - by Disease
        • 10.1.1.4.3 Mexico: North America Genetic Testing Services Market Share - by Cancer Disease
        • 10.1.1.4.4 Mexico: North America Genetic Testing Services Market Share - by Service Providers

11. Genetic Testing Services Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Genetic Testing Services Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Eurofins Scientific SE
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Exact Sciences Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Laboratory Corp of America Holdings
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 23andMe Holding Co
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Ambry Genetics Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Quest Diagnostics Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Illumina Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 F. Hoffmann-La Roche Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 NeoGenomics Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Centogene NV
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Ancestry Genomics Inc
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments
  • 12.12 Gene By Gene Ltd
    • 12.12.1 Key Facts
    • 12.12.2 Business Description
    • 12.12.3 Products and Services
    • 12.12.4 Financial Overview
    • 12.12.5 SWOT Analysis
    • 12.12.6 Key Developments
  • 12.13 SIVOTEC BioInformatics LLC
    • 12.13.1 Key Facts
    • 12.13.2 Business Description
    • 12.13.3 Products and Services
    • 12.13.4 Financial Overview
    • 12.13.5 SWOT Analysis
    • 12.13.6 Key Developments
  • 12.14 Progenesis
    • 12.14.1 Key Facts
    • 12.14.2 Business Description
    • 12.14.3 Products and Services
    • 12.14.4 Financial Overview
    • 12.14.5 SWOT Analysis
    • 12.14.6 Key Developments
  • 12.15 Fulgent Genetics, Inc
    • 12.15.1 Key Facts
    • 12.15.2 Business Description
    • 12.15.3 Products and Services
    • 12.15.4 Financial Overview
    • 12.15.5 SWOT Analysis
    • 12.15.6 Key Developments
  • 12.16 VERITAS INTERCONTINENTAL
    • 12.16.1 Business Description
    • 12.16.2 Products and Services
    • 12.16.3 Financial Overview
    • 12.16.4 SWOT Analysis
    • 12.16.5 Key Developments
  • 12.17 GeneDx, LLC
    • 12.17.1 Key Facts
    • 12.17.2 Business Description
    • 12.17.3 Products and Services
    • 12.17.4 Financial Overview
    • 12.17.5 SWOT Analysis
    • 12.17.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Genetic Testing Services Market Segmentation
  • Table 2. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Service Type
  • Table 4. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Disease
  • Table 5. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Service Providers
  • Table 6. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 7. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
  • Table 8. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease
  • Table 9. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cancer Disease
  • Table 10. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Providers
  • Table 11. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
  • Table 12. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease
  • Table 13. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cancer Disease
  • Table 14. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Providers
  • Table 15. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
  • Table 16. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease
  • Table 17. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cancer Disease
  • Table 18. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Providers
  • Table 19. Recent Organic Growth Strategies in Genetic Testing Services Market
  • Table 20. Recent Inorganic Growth Strategies in the Genetic Testing Services Market
  • Table 21. Glossary of Terms, Genetic Testing Services Market

List Of Figures

  • Figure 1. North America Genetic Testing Services Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Genetic Testing Services Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Genetic Testing Services Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Genetic Testing Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 7. Predictive Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. carrier testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Prenatal Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. New-born Screening: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Diagnostic Genetic Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Others: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. North America Genetic Testing Services Market Share (%) - by Disease (2023 and 2031)
  • Figure 14. Cancer: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Cardiovascular Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Metabolic Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Other Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. North America Genetic Testing Services Market Share (%) - by Service Providers (2023 and 2031)
  • Figure 19. Hospital-Based Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Diagnostic Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Other Service Providers: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. North America Genetic Testing Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. Growth Strategies in Genetic Testing Services Market